Quick Takeaways: Why It Matters? OST-HER2’s potential conditional licensure could give OSAH a first-mover advantage in HER2-targeted canine osteosarcoma, an area with limited treatment options. A 2027 launch could establish a differentiated oncology franchise, while validating ...
Quick Takeaways: Why It Matters? AKS-699 is being positioned as a long-interval, owner-friendly alternative to monthly IL‑31 biologics like Cytopoint in canine atopic dermatitis. The favorable efficacy and tolerability profile in preclinical work (only mild, transient injection-site r...
Quick Takeaways: Why It Matters? VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia. The clinical data in aged Beagles shows a single...
